12:00 AM
 | 
Jul 05, 2000
 |  BC Extra  |  Company News

Cell Pathways to market Aventis' Nilandron

CLPA obtained rights to market AVE's Nilandron nilutamide to urologists...

Read the full 28 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >